GAITHERSBURG, Md., July 27 /PRNewswire-FirstCall/ -- Today GenVec, Inc. (Nasdaq: GNVC) announced the expansion of an existing contract with the PATH Malaria Vaccine Initiative (MVI) to support the development of vaccines to fight malaria through MVI and USAID funding. This contract, valued at approximately $2 million, will continue a collaboration that began in 2004 and will initially support preclinical feasibility studies of novel adenovirus-based vaccines. Based on the results of the feasibility studies, GenVec, MVI, and USAID will contemplate preclinical and clinical development of these vaccines.
"We appreciate the continued support from MVI and USAID and we look forward to advancing GenVec's vaccine technology through this collaboration," stated Dr. Joseph Bruder, head of GenVec's malaria program.
GenVec, Inc. is a biopharmaceutical company developing novel therapeutic drugs and vaccines. GenVec's lead product, TNFerade(TM), is currently in a pivotal clinical study (PACT) in locally advanced pancreatic cancer. TNFerade has also been and is currently being evaluated for its potential use in the treatment of several other cancers, including esophageal cancer, rectal cancer, and head and neck cancer. GenVec also uses its proprietary adenovector technology to develop vaccines for infectious diseases including HIV, malaria, foot-and-mouth disease, respiratory syncytial virus (RSV), and HSV-2. Additional information about GenVec is available at www.genvec.com and in the company's various filings with the Securities and Exchange Commission.
On the Internet:
Program for Appropriate Technology in Health (PATH):
PATH Malaria Vaccine Initiative:
USAID Malaria Vaccine Development Program: www.usaid.gov/our_work/global_health/id/malaria/techareas/vaccine.html
Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding future revenues and operating expenses, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to clinical trials; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of third parties; dependence on intellectual property; and risks that we may lack the financial resources and access to capital to fund our operations. Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.
|SOURCE GenVec, Inc.|
Copyright©2009 PR Newswire.
All rights reserved